CTCF Rabbit anti-Human, Polyclonal, Bioss
Manufacturer: Bioss
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | 50-198-5644-Each-of-1 | In Stock | ₹ 38,381.25 |
50-198-5644 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 38,381.25
GST (18%): ₹ 6,908.625
Total Price: ₹ 45,289.875
Antigen
CTCF
Classification
Polyclonal
Conjugate
Unconjugated
Gene
CTCF
Gene Alias
11 zinc finger transcriptional repressor; 11-zinc finger protein; AW108038; BOS_17095; CCCTC-binding factor; CCCTC-binding factor (zinc finger protein); CTCF; ctcf protein; CTCFL paralog; im:7152666; MRD21; OTTHUMP00000197610; Transcriptional repressor CTCF; Unknown (protein for IMAGE:8125283)
Host Species
Rabbit
Purification Method
Protein A
Regulatory Status
RUO
Gene ID (Entrez)
10664
Content And Storage
-20°C
Form
Liquid
Applications
Immunofluorescence, Immunohistochemistry (Paraffin), Western Blot
Concentration
1 μg/mL
Formulation
PBS with 1% BSA, 50% glycerol and 0.09% sodium azide; pH
Gene Accession No.
P49711
Gene Symbols
CTCF
Immunogen
KLH conjugated synthetic peptide derived from human CTCF .
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG
Related Products
Description
- Transcriptional factor CTCF is a ubiquitously expressed 11-zinc finger domain containing, DNA-binding nuclear phosphoprotein that is involved in multiple aspects of normal gene regulation including transcriptional repression and activation, gene silencing, chromatin insulation and regulation of imprinted sites
- CTCF uses different combinations of ZF domains and interacts with the CCCTC motif on the DNA
- It can bind to HAT- and HDAC-containing complexes thereby influencing transcriptional activation or repression respectively
- It is a multifunctional protein involved in the transactivation of APPB gene, silencing of c-myc gene, and insulation of human beta-globin and DMI myotonic dystrophy locus and imprinting control of IGF2 and H19 regions
- CTCF has also been shown to regulate the transcription of Pax6 and IRAK2 promoter thereby opening a therapeutic avenue
- Mutations in this gene have been associated with invasive breast cancers, prostate cancers and Wilms′ tumors.